While the US Supreme Court ruled that the inter partes review (IPR) process is constitutional, AbbVie Inc. and Genentech Inc. contend that it left the door open to challenge the retroactive application of the proceeding. They are now trying to walk through that door.
Challenging decisions by the US Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) that invalidated their patents, they...





